Propofol is a lipid-based potent intravenous hypnotic agent associated with rapid induction, smooth maintenance and early recovery in anaesthesia 1, 2 . There have been more than 25 reported cases of propofol-induced acute pancreatitis in the literature 3, 4 . Significant elevation of serum triglyceride has also been reported with prolonged infusions of propofol 1, 5 . Some cases of acute pancreatitis have also been reported following a single dose of propofol 4, 6 .
At present, it is not clear whether the elevation of enzymes and triglycerides following propofol administration is dose-related or idiosyncratic. Hence, a prospective study was planned to assess the dose-related effect of short-term intraoperative administration of propofol on pancreatic enzymes and serum triglyceride levels.
METHODS
After institutional ethics committee approval and obtaining written informed consent, a prospective study was conducted in which 150 patients in the age group of 18 to 60 years, belonging to ASA physical status I and II, undergoing non-abdominal surgery were divided into three groups (groups I, II and III). In this non-randomised study, patients undergoing shorter duration of surgery were included in group I, while patients undergoing longer duration of surgery were included in groups II and III alternately.
Patients with diabetes, morbid obesity, gall stone disease, lipoproteinaemias, hypercalcaemia or a history of pancreatitis were excluded. Patients undergoing cardiac surgery or receiving drugs SuMMARy Various case reports have indicated a possible relationship between propofol and pancreatitis. However, it is not clear whether this relationship (if any) is dose-related or idiosyncratic. Therefore, a prospective study was conducted to evaluate the effect of different doses of propofol on postoperative pancreatic enzymes and serum triglyceride levels. One hundred and fifty patients, aged 18 to 60 years, belonging to ASA physical status I and II, undergoing non-abdominal surgery were divided into three groups. Anaesthesia was induced with propofol 2 to 2.5 mg/kg in all groups. It was maintained with isoflurane in group I, propofol infusion <5 mg/kg/h in group II and propofol infusion ≥5 mg/kg/h in group III. All three groups also received nitrous oxide in oxygen for maintenance of anaesthesia. Serum amylase, lipase and triglyceride were estimated before propofol administration and at 24 and 72 hours postoperatively.
The mean values of serum amylase, lipase and triglyceride remained within the normal range in the three groups. These values did not differ significantly in between the groups even despite the significantly different doses of propofol in the three groups (P <0.001). None of the patients in the three groups developed any feature suggestive of acute pancreatitis in the postoperative period.
These findings indicate that propofol administration at recommended doses does not produce dose-related increases in pancreatic enzyme and triglyceride levels in ASA physical status I and II patients.
known to affect pancreatic functions (such as azathioprine, 6-mercaptopurine, oestrogen, thiazide, frusemide, tetracycline, valproate) were also excluded.
During the pre-anaesthetic assessment, age, gender, height, weight, history of alcohol abuse or any systemic illness were recorded. A note was made about any history of previous exposure to propofol. Preoperative serum amylase, lipase and triglyceride values were also estimated. Patients were divided into three groups of 50 patients in each group. Anaesthesia was induced with propofol 2 to 2.5 mg/kg in all the three groups and maintained in group I with oxygen, nitrous oxide and isoflurane. Patients in groups II and III received propofol infusion at the rate of 2 to 4 mg/kg/h and 5 to 8 mg/kg/h respectively along with oxygen and nitrous oxide (70%) for maintenance of anaesthesia. All patients received morphine 0.1 mg/kg for analgesia and vecuronium 0.1mg/kg to facilitate intubation. Intermittent top-ups of vecuronium (0.02 mg/kg) were used to maintain muscle relaxation.
All patients were monitored for heart rate, systolic, diastolic and mean arterial pressure, arterial oxygen saturation during the intraoperative period at fiveminute intervals until the end of anaesthesia. The duration of surgery and anaesthesia, total dose of propofol, opioids and muscle relaxant used and total volume of intravenous fluids administered intraoperatively were also recorded. Any episode of haemodynamic instability was treated by an intravenous bolus of fluid and was recorded if it was both prolonged (>10 minutes) and severe (<60 mmHg mean blood pressure) requiring administration of vasopressors or inotropes. Serum amylase, lipase and triglyceride were measured preoperatively and at 24 and 72 hours after surgery. Presence of signs and symptoms of acute pancreatitis such as abdominal pain radiating to the back, abdominal distension, nausea and vomiting, fever, tachycardia and hypotension were recorded at six-hour intervals in the first 24 hours and at 12-hour intervals until 72 hours in the postoperative period.
The primary endpoint of our study was to assess the changes in postoperative serum amylase, lipase and triglyceride levels in relation to the dose of propofol administered during intraoperative period.
Serum amylase and lipase estimation was measured using a Roche automated clinical chemistry analyser by enzymatic colorimetric assay. Serum amylase was estimated by cleavage of 4,6-ethylidene-(G 7 )-1,4-nitrophenyl-G 1 )-α,D-maltoheptaoside by αamylase and subsequent hydrolysis to p-nitrophenol with the aid of α-glucosidase. The colour intensity of p-nitrophenol formed was directly proportional to α-amylase activity and was measured photometrically. Serum lipase estimation was based on the cleavage of 1,2-O-dilauryl-rac-glycero-3-glutaric acid-(6methylresorufin) ester emulsified with bile acids. The colour intensity of the red dye formed was directly proportional to the lipase activity and was determined photometrically. Serum triglyceride was estimated using the Roche clinical chemistry analyser. The method of estimation was based on the work by Wahlefeld using a lipoprotein lipase from a micro-organism for the rapid and complete hydrolysis of triglycerides to glycerol followed by oxidation to dihydroacetone phosphate and hydrogen peroxide. The hydrogen peroxide produced then reacts with 4-aminophenanzone and 4-chlorophenol under the catalytic action of peroxidase to form a red dyestuff whose intensity was determined photometrically.
The normal values for pancreatic amylase were 29 to 100 Iu/l, serum lipase 40 to 100 Iu/l and serum triglyceride 50 to 200 mg/dl.
Statistical analysis was performed using SPSS (SPSS 15.0, SPSS Inc, Chicago, II, uSA). Data are presented as mean and standard deviation. The parametric data (age, weight, height), anaesthetic drug dosages, durations of surgery and anaesthesia were analysed using one-way analysis of variance (ANOVA) with Bonferroni post-hoc tests. Plasma amylase, lipase and triglyceride levels were analysed using one-way ANOVA with Bonferroni post-hoc tests for inter-group comparisons and repeated measures ANOVA and paired t-tests were used for intragroup comparisons. P values less than 0.05 were considered as statistically significant.
RESuLTS
Patients in the three groups were comparable with respect to age, weight, height and gender distribution. No significant differences were found between the groups in terms of associated comorbid illness or ASA status, history of alcohol consumption and previous exposure to propofol ( Table 1) . As expected, the mean durations of surgery and anaesthesia were significantly longer in groups II and III compared to group I. Similarly, total propofol dosage administered also differed significantly in between the groups ( Table 2) . Haemodynamic variables in terms of heart rate, blood pressure, SpO 2 were not significantly different in all the three groups and no patient required inotropic support to maintain blood pressure in the intraoperative period. The baseline values of serum amylase, lipase and triglyceride were normal in all the three groups. There was a minimal rise in the mean values of the enzyme levels at 24 and 72 hours in all three groups, but this was not clinically relevant (i.e. only 1 to 2 units). Moreover, all the values remained within normal range (Table 3 ). Comparison between the groups did not show any statistically significant differences in the values of these enzymes at baseline, 24 hours and 72 hours ( Table 4 ). None of the patients in any of the groups experienced symptoms or signs suggestive of acute pancreatitis in the postoperative period.
DISCuSSION
We observed that the use of propofol in the intraoperative period in recommended doses did not produce a clinically relevant rise in the pancreatic enzyme or triglyceride levels and all values remained within the normal range. The maximum values of serum amylase at any time during the study period in groups I, II and III were 100, 100 and 98 Iu/l respectively, which were within the normal range (29 to 100 Iu/l). Though there was a statistically significant rise in serum amylase levels postoperatively in all three groups, the increases were not clinically relevant (Table 3 ). In contrast, case reports in which propofol was linked to pancreatitis reported rises in serum amylase values as high as 2270, 2902, 3872 Iu/l 4, 6, 7 .
In this study, the lipase levels were found to be in the range of 70 to 92, 66 to 90, 52 to 88 Iu/l in groups I, II and III respectively. Again, although the rise seen in postoperative lipase levels was statistically significant in groups II and III, the values remained within normal limits (40 to 100 Iu/l, Table 3 ). Jawaid et al 8 reported a rise in serum lipase to 13,287 u/l in a patient who received propofol 150 mg.
Case reports suggesting propofol-induced pancreatitis have reported serum triglyceride values as high as 1000 mg/dl 9 . The maximum values of serum triglyceride observed in our study in groups I, II and III were 117, 98 and 145 mg/dl respectively and all values were well within the normal limits ( Table 3) .
The absence of an increase above the normal range in any of the patients, even in the groups receiving the highest dose of propofol, suggests that there is no dose-related increase in these enzyme and triglyceride levels when propofol is used intraoperatively in recommended doses in ASA physical status I and II patients.
In this non-randomised study, we incorporated patients undergoing both short and long duration surgery. In short duration surgery, only a single bolus dose of propofol was used for induction of anaesthesia while in long surgery, propofol was used for both induction and maintenance of anaesthesia. This explains a significant difference seen in the duration of surgery, anaesthesia and total dose of propofol used between the groups (Table 2) . Otherwise, all three groups were comparable demographically and in relation to the presence of comorbid diseases, ASA physical status, alcohol consumption and previous history of exposure to propofol ( Table 1 ). For homogeneity of data, we included patients undergoing only non-abdominal surgery, as intra-abdominal surgery, particularly upper abdominal surgery could be associated with other causes for a rise in pancreatic enzymes 10 .
As our study was mainly concerned with dose of propofol and serum biochemical results and the person in-charge of biochemical tests was blinded to the aim of the study, any chance of bias was unlikely.
Our findings are in part, similar to the results obtained by a prospective study conducted by Donmez et al 11 in 40 patients divided into two groups. Patients in group I received propofol both for induction and maintenance of anaesthesia, while those in group II received thiopentone for induction and isoflurane for maintenance of anaesthesia. The authors did not find any significant increase in serum amylase, lipase, cholesterol or triglyceride values 24 hours postoperatively in patients who received propofol. In contrast, Gottschling et al 12 found a statistically significant rise in lipase levels from 23.8 to 27.3 u/l and triglyceride levels from 106 to 141.9 mg/dl in a study conducted on 40 children who received propofol infusion for sedation during magnetic resonance imaging, when propofol was used in a loading dose of 2.2 mg/kg followed by an infusion rate of 6.9 mg/kg/h for a mean duration of 46 minutes.
Propofol is an alkyl phenol (2, 6-diisopropyl phenol) and is formulated as a 1% emulsion containing 10% soybean oil, 2.25% glycerol and 1.2% purified egg phosphatide with disodium edetate or sodium metabisulphite added as a preservative 2 . Significant elevation of serum triglyceride levels has been reported with prolonged infusions of propofol 1, 3, 13 . Hypertriglyceridaemia is seen in 12 to 38% of patients presenting with acute pancreatitis 8, 14, 15 . Studies have found that long-term hypertriglyceridaemia at levels of 1000 to 2000 mg/dl is necessary to cause hyperlipidaemic pancreatitis 16 .
The triglyceride levels observed in our study (48 to 145 mg/dl) would be unlikely to cause acute pancreatitis.
Devlin et al 10 conducted a retrospective study in medical and surgical intensive care units in patients who received propofol for more than 24 hours. They observed that out of 159 patients, 29 (18%) developed hypertriglyceridaemia (≥400 mg/dl), six (4%) had a serum triglyceride concentration of 1000 mg/dl or greater and three (2%) developed pancreatitis. In contrast, in our study, though serum triglycerides levels were increased slightly in the postoperative period, the values remained within normal range.
In another prospective study conducted by Piper et al 17 in 42 patients, propofol was compared with midazolam infusion for sedation in the intensive care unit. They reported significantly higher levels of serum triglyceride four hours after starting the infusion in the propofol group (140 mg/dl) than in midazolam group (81 mg/dl). However they did not find significant increases in serum amylase, lipase, cholesterol or pancreatitis associated protein values, even in patients receiving higher doses of propofol (mean 1292 mg) for a longer period (nine hours).
While various prospective and retrospective studies have been peformed to investigate the incidence of propofol induced pancreatitis, there have been inconsistent results. Isolated case reports have shown very high values of serum enzymes and a possible link between propofol and acute pancreatitis. In the absence of a dose-related effect, it may be postulated that this link, if any, is idiosyncratic and that only certain individuals are prone to develop acute pancreatitis following propofol. In order to investigate such idiosyncratic reactions, a much large sample size of several thousand patients would have been required to have sufficient power. This was outside the scope of the current study.
We therefore conclude that propofol administration at recommended doses, either as a single bolus dose or short-term infusion in the intraoperative period in ASA physical status I and II, does not cause dose-related increases in pancreatic enzyme or triglyceride levels in patients undergoing elective non-abdominal surgery.
